lapatinib has been researched along with repaglinide in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (repaglinide) | Trials (repaglinide) | Recent Studies (post-2010) (repaglinide) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 610 | 152 | 244 |
| Protein | Taxonomy | lapatinib (IC50) | repaglinide (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 9.2 | |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | 9.2 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.106 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for lapatinib and repaglinide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |